Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ZYME
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Mark Hollywood EVP & Chief Operating Officer | ZYME Zymeworks Inc. | Sale | 6,120 | $22.67 | $138.7K Sale | Form 4 ↗ |
| Jan 12, 2026 | Jeffrey T. L. Smith EVP & Chief Medical Officer | ZYME Zymeworks Inc. | Sale | 9,310 | $22.67 | $211.1K Sale | Form 4 ↗ |
| Jan 12, 2026 | Paul Andrew Moore Chief Scientific Officer | ZYME Zymeworks Inc. | Sale | 9,560 | $22.67 | $216.7K Sale | Form 4 ↗ |
| Jan 12, 2026 | Kenneth Galbraith Chair & CEO, Director | ZYME Zymeworks Inc. | Sale | 30,424 | $22.67 | $689.7K Sale | Form 4 ↗ |
| Jan 5, 2026 | Jeffrey T. L. Smith EVP & Chief Medical Officer | ZYME Zymeworks Inc. | Sale | 10,538 | $25.10 | $264.5K Sale | Form 4 ↗ |
| Jan 5, 2026 | Kenneth Galbraith Chair & CEO, Director | ZYME Zymeworks Inc. | Sale | 31,686 | $25.10 | $795.3K Sale | Form 4 ↗ |
| Jan 5, 2026 | Kenneth Galbraith Chair & CEO, Director | ZYME Zymeworks Inc. | Sale | 22,657 | $25.10 | $568.7K Sale | Form 4 ↗ |
| Jan 5, 2026 | Paul Andrew Moore Chief Scientific Officer | ZYME Zymeworks Inc. | Sale | 10,821 | $25.10 | $271.6K Sale | Form 4 ↗ |
| Jan 5, 2026 | Paul Andrew Moore Chief Scientific Officer | ZYME Zymeworks Inc. | Sale | 9,289 | $25.10 | $233.2K Sale | Form 4 ↗ |
| Dec 22, 2025 | Kenneth Galbraith Chair & CEO, Director | ZYME Zymeworks Inc. | Sale | 47,528 | $27.02 | $1.3M Sale | Form 4 ↗ |
| May 19, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 5,919 | $11.78 | $69.7K Buy | Form 4 ↗ |
| May 15, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 49,502 | $11.43 | $565.8K Buy | Form 4 ↗ |
| Apr 17, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 54,760 | $11.52 | $630.8K Buy | Form 4 ↗ |
| Apr 16, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 73,953 | $11.16 | $825.3K Buy | Form 4 ↗ |
| Apr 4, 2025 | Oleg Nodelman Director, 10% owner | ZYME Zymeworks Inc. | Buy | 196,438 | $11.17 | $2.2M Buy | Form 4 ↗ |
| Apr 3, 2025 | Oleg Nodelman Director, 10% owner | ZYME Zymeworks Inc. | Buy | 120,770 | $11.84 | $1.4M Buy | Form 4 ↗ |
| Apr 2, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 74,360 | $11.85 | $881.2K Buy | Form 4 ↗ |
| Apr 1, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 48,658 | $11.60 | $564.4K Buy | Form 4 ↗ |
| Mar 31, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 4,397 | $11.75 | $51.7K Buy | Form 4 ↗ |
| Mar 26, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 43,848 | $12.24 | $536.7K Buy | Form 4 ↗ |
| Mar 25, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 53,501 | $12.91 | $690.7K Buy | Form 4 ↗ |
| Mar 24, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 22,689 | $13.08 | $296.8K Buy | Form 4 ↗ |
| Mar 21, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 31,033 | $12.78 | $396.6K Buy | Form 4 ↗ |
| Mar 20, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 73,476 | $12.93 | $950.0K Buy | Form 4 ↗ |
| Mar 19, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 58,306 | $12.64 | $737.0K Buy | Form 4 ↗ |
| Mar 18, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 113,880 | $12.65 | $1.4M Buy | Form 4 ↗ |
| Mar 17, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 56,277 | $12.23 | $688.3K Buy | Form 4 ↗ |
| Mar 13, 2025 | Oleg Nodelman Director, 10% owner | ZYME Zymeworks Inc. | Buy | 468,356 | $12.48 | $5.8M Buy | Form 4 ↗ |
| Mar 12, 2025 | Oleg Nodelman Director, 10% owner | ZYME Zymeworks Inc. | Buy | 292,934 | $12.25 | $3.6M Buy | Form 4 ↗ |
| Mar 11, 2025 | Oleg Nodelman Director, 10% owner | ZYME Zymeworks Inc. | Buy | 320,690 | $11.49 | $3.7M Buy | Form 4 ↗ |
| Jan 17, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 19,748 | $13.87 | $273.9K Buy | Form 4 ↗ |
| Jan 16, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 121,681 | $13.89 | $1.7M Buy | Form 4 ↗ |
| Jan 15, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 39,029 | $14.01 | $546.8K Buy | Form 4 ↗ |
| Jan 14, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 54,500 | $13.56 | $739.0K Buy | Form 4 ↗ |
| Jan 13, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 74,125 | $13.39 | $992.5K Buy | Form 4 ↗ |
| Jan 10, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 204,098 | $13.13 | $2.7M Buy | Form 4 ↗ |
| Jan 8, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 21,021 | $14.07 | $295.8K Buy | Form 4 ↗ |
| Jan 6, 2025 | Paul Andrew Moore Chief Scientific Officer | ZYME Zymeworks Inc. | Sale | 11,408 | $14.92 | $170.2K Sale | Form 4 ↗ |
| Jan 6, 2025 | Paul Andrew Moore Chief Scientific Officer | ZYME Zymeworks Inc. | Sale | 9,792 | $14.92 | $146.1K Sale | Form 4 ↗ |
| Jan 6, 2025 | Kenneth Galbraith Chair & CEO, Director | ZYME Zymeworks Inc. | Sale | 33,406 | $14.92 | $498.4K Sale | Form 4 ↗ |
| Jan 6, 2025 | Kenneth Galbraith Chair & CEO, Director | ZYME Zymeworks Inc. | Sale | 23,885 | $14.92 | $356.4K Sale | Form 4 ↗ |
| Jan 6, 2025 | Jeffrey T. L. Smith EVP & Chief Medical Officer | ZYME Zymeworks Inc. | Sale | 11,110 | $14.92 | $165.8K Sale | Form 4 ↗ |
| Jan 2, 2025 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 157,880 | $14.78 | $2.3M Buy | Form 4 ↗ |
| Dec 31, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 146,501 | $14.57 | $2.1M Buy | Form 4 ↗ |
| Dec 30, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 58,988 | $14.47 | $853.6K Buy | Form 4 ↗ |
| Dec 27, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 101,659 | $14.49 | $1.5M Buy | Form 4 ↗ |
| Dec 26, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 16,692 | $14.38 | $240.0K Buy | Form 4 ↗ |
| Dec 24, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 11,958 | $14.12 | $168.8K Buy | Form 4 ↗ |
| Dec 23, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 251,502 | $14.25 | $3.6M Buy | Form 4/A ↗ |
| Dec 20, 2024 | EcoR1 Capital, LLC Director, 10% owner | ZYME Zymeworks Inc. | Buy | 704,488 | $14.08 | $9.9M Buy | Form 4/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:27 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances